Cytochrome P-450 CYP2D6

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is a stub and thus not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.
Crystal Structure of Human Cytochrome P450 2d6.

In biology, the cytochrome P-450 CYP2D6 is a "cytochrome P-450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as debrisoquine; adrenergic receptor antagonists; and tricyclic antidepressants. This enzyme is deficient in up to 10 percent of the Caucasian population."[1][2]

CYP2D6 may be responsible for metabolism of 25% of prescribed drugs[3] and 38% of drugs frequently cited for causing drug toxicity[4].

Paroxetine may increase death from breast cancer among women taking tamoxifen due to inhibiting metabolism of tamoxifen to its active metabolite by cytochrome P-450 CYP2D6.[5]

External links


  1. Anonymous (2015), Cytochrome P-450 CYP2D6 (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Online Mendelian Inheritance in Man, OMIM®. Johns Hopkins University, Baltimore, MD. MIM Number: 608902. World Wide Web URL:
  3. Wolf CR, Smith G (1999). "Pharmacogenetics.". Br Med Bull 55 (2): 366-86. PMID 10723863.
  4. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W (2001). "Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.". JAMA 286 (18): 2270-9. PMID 11710893.
  5. Kelly, Catherine M; David N Juurlink, Tara Gomes, Minh Duong-Hua, Kathleen I Pritchard, Peter C Austin, Lawrence F Paszat (2010-02-08). "Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study". BMJ 340 (feb08_1): c693. DOI:10.1136/bmj.c693. Retrieved on 2010-02-10. Research Blogging.